A Phase 3 interventional study of PCV21 vaccine and Vaxneuvance vaccine in Pneumococcal Immunization and Healthy Volunteers, sponsored by Sanofi. Active, not recruiting at 49 sites in 8 countries. Open to participants aged 42 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days).
The study duration per participant will be up to approximately 20 months. The study vaccines (either PCV21 or 15-valent pneumococcal vaccines) will be administered at approximately 2, 4, and 11 to 15 months of age or at approximately 2, 3, 4, and 11 to 15 months of age (for preterm infants). Routine pediatric vaccines will be given at the same timepoints, as per local practice / recommendations.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered via intramuscular injection (IM) a 2-dose primary series of PCV21 at approximately 2 and 4 months of age (MoA) or a 3-dose primary series (preterm infants) at 2, 3, and 4 MoA co- administered with Hexyon. At 11 to 15 MoA, participants will receive a 3rd dose or 4th dose (for preterm infants) of PCV21 co-administered with Hexyon and M M RvaxPro; Varivax will also be co-administered unless not possible as per local practice
Biological: PCV21 vaccine · Biological: Hexyon vaccine · Biological: M-M-RvaxPro vaccine · Biological: Varivax vaccine
Participants will be administered via intramuscular injection (IM) a 2-dose primary series of 15vPCV at approximately 2 and 4 months of age (MoA) or a 3-dose primary series (preterm infants) at 2, 3, and 4 MoA co- administered with Hexyon. At 11 to 15 MoA, participants will receive a 3rd dose or 4th dose (for preterm infants) of 15vPCV co-administered with Hexyon and M M RvaxPro; Varivax will also be co-administered unless not possible as per local practice
Biological: Vaxneuvance vaccine · Biological: Hexyon vaccine · Biological: M-M-RvaxPro vaccine · Biological: Varivax vaccine
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Also known as: 515
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Also known as: Vaxneuvance ™
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Also known as: Hexyon®
Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
Also known as: M-M-RVAX-PRO®
Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
Also known as: Varivax®
Seroresponse rate for PCV21 and 15vPCV serotypes
Serotype specific IgG concentration ≥ 0.35 µg/mL
Time frame: 30 days post-toddler dose
IgG concentration for PCV21 and 15vPCV serotypes
Serotype specific IgG Geometric Mean Concentration (GMC)
Time frame: 30 days post-toddler dose
Anti- hepatitis B surface antigen (HBsAg) Ab
% Antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL)
Time frame: 30 days post-toddler dose
Anti- polyribosylribitol phosphate (PRP) Ab
% Antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL)
Time frame: 30 days post-toddler dose
Anti-poliovirus types (1, 2, and 3) Ab
% Antibody titers ≥ 1:8
Time frame: 30 days post-toddler dose
Anti-diphtheria Ab concentrations
% Antibody concentration ≥ 0.1 IU/mL
Time frame: 30 days post-toddler dose
Anti-tetanus Ab concentrations
% Antibody concentration ≥ 0.1 IU/mL
Time frame: 30 days post-toddler dose
Anti-pertussis Ab concentrations (Pertussis toxin (PT) and Filamentous Hemagglutinin (FHA))
Antibody GMC
Time frame: 30 days post-toddler dose
Anti-measles Ab concentrations
Antibody GMC
Time frame: 30 days post-toddler dose
Anti-mumps Ab concentrations
Antibody GMC
Time frame: 30 days post-toddler dose
Anti-rubella Ab concentrations
Antibody GMC
Time frame: 30 days post-toddler dose
Anti-varicella Ab concentrations
Antibody GMC
Time frame: 30 days post-toddler dose
Anti HBsAg concentrations
% Antibody concentrations ≥ 10 mIU/mL
Time frame: 30 days post-primary series
Anti-PRP Ab concentrations
% Antibody concentrations ≥ 0.15 µg/mL
Time frame: 30 days post-primary series
Anti-poliovirus types (1, 2, and 3) Ab titers
% Antibody titers ≥ 1:8
Time frame: 30 days post-primary series
Anti-diphtheria Ab concentrations
% Antibody concentrations ≥ 0.1 IU/mL
Time frame: 30 days post-primary series
Anti-tetanus Ab concentrations
% Antibody concentrations ≥ 0.1 IU/mL
Time frame: 30 days post-primary series
Anti-pertussis Ab concentrations (PT and FHA)
Antibody GMC
Time frame: 30 days post-primary series
Serotype specific OPA titers for all serotypes included in PCV21
Antibody Geometric mean titer (GMT)
Time frame: 30 days post-primary series
Serotype specific OPA titers for all serotypes included in PCV21
Antibody GMT
Time frame: 30 days post-toddler dose
Presence of any immediate adverse events (AEs)
Number of participants experiencing immediate AEs
Time frame: Within 30 minutes after each vaccine injection
Presence of solicited injection site and systemic reactions through 7 days after each vaccine injection
Number of participants experiencing solicited injection site and systemic reactions
Time frame: Through 7 days after each vaccine injection
Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injection
Number of participants experiencing unsolicited injection site reactions and unsolicited systemic AEs
Time frame: Through 30 days after each vaccine injection
Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)
Number of participants experiencing SAEs
Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 20 months
Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)
Number of participants experiencing AESIs
Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 20 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine